Abstract |
Enhancer of Zeste Homolog 2 (EZH2) and androgen receptor (AR) are crucial chromatin/gene regulators involved in the development and/or progression of prostate cancer, including advanced castration-resistant prostate cancer (CRPC). To sustain prostate tumorigenicity, EZH2 establishes non-canonical biochemical interaction with AR for mediating oncogene activation, in addition to its canonical role as a transcriptional repressor and enzymatic subunit of Polycomb Repressive Complex 2 (PRC2). However, the molecular basis underlying non-canonical activities of EZH2 in prostate cancer remains elusive, and a therapeutic strategy for targeting EZH2:AR-mediated oncogene activation is also lacking. Here, we report that a cryptic transactivation domain of EZH2 (EZH2TAD) binds both AR and AR spliced variant 7 (AR-V7), a constitutively active AR variant enriched in CRPC, mediating assembly and/or recruitment of transactivation-related machineries at genomic sites that lack PRC2 binding. Such non-canonical targets of EZH2:AR/AR-V7:(co-)activators are enriched for the clinically relevant oncogenes. We also show that EZH2TAD is required for the chromatin recruitment of EZH2 to oncogenes, for EZH2-mediated oncogene activation and for CRPC growth in vitro and in vivo. To completely block EZH2's multifaceted oncogenic activities in prostate cancer, we employed MS177, a recently developed proteolysis-targeting chimera ( PROTAC) of EZH2. Strikingly, MS177 achieved on-target depletion of both EZH2's canonical (EZH2:PRC2) and non-canonical (EZH2TAD:AR/AR-V7:co-activators) complexes in prostate cancer cells, eliciting far more potent antitumor effects than the catalytic inhibitors of EZH2. Overall, this study reports a previously unappreciated requirement for EZH2TAD for mediating EZH2's non-canonical (co-)activator recruitment and gene activation functions in prostate cancer and suggests EZH2-targeting PROTACs as a potentially attractive therapeutic for the treatment of aggressive prostate cancer that rely on the circuits wired by EZH2 and AR.
|
Authors | Jun Wang, Kwang-Su Park, Xufen Yu, Weida Gong, H Shelton Earp, Gang Greg Wang, Jian Jin, Ling Cai |
Journal | Nucleic acids research
(Nucleic Acids Res)
Vol. 50
Issue 19
Pg. 10929-10946
(10 28 2022)
ISSN: 1362-4962 [Electronic] England |
PMID | 36300627
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural)
|
Copyright | © The Author(s) 2022. Published by Oxford University Press on behalf of Nucleic Acids Research. |
Chemical References |
- Chromatin
- Enhancer of Zeste Homolog 2 Protein
- EZH2 protein, human
- Polycomb Repressive Complex 2
- Receptors, Androgen
- Protein Isoforms
|
Topics |
- Humans
- Male
- Cell Line, Tumor
- Chromatin
(genetics)
- Enhancer of Zeste Homolog 2 Protein
(metabolism)
- Gene Expression Regulation, Neoplastic
- Oncogenes
- Polycomb Repressive Complex 2
(genetics, metabolism)
- Prostatic Neoplasms, Castration-Resistant
(pathology)
- Receptors, Androgen
(genetics, metabolism)
- Transcriptional Activation
- Protein Isoforms
|